



Briviact® (brivaracetam) – Expanded indication

- On May 14, 2018, [UCB announced](#) the FDA approval of [Briviact \(brivaracetam\)](#) tablets and oral solution, for the treatment of partial-onset seizures in patients 4 years of age and older.
 - Previously, Briviact was approved for the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
 - As the safety of Briviact injection in pediatric patients has not been established, Briviact injection is indicated for the treatment of partial-onset seizures only in adult patients (16 years of age and older).
 - Briviact is a schedule V controlled substance.
- Epilepsy is a chronic neurological disorder of the brain. It is estimated that nearly 470,000 children in the U.S. under the age of 18 have epilepsy.
- The safety and effectiveness of Briviact tablets and oral solution have been established in pediatric patients 4 years to less than 16 years of age.
 - Use of Briviact in these age groups is supported by evidence from adequate and well-controlled studies of Briviact in adults with partial-onset seizures, pharmacokinetic data from adult and pediatric patients, and safety data in 149 pediatric patients 4 years to less than 16 years of age.
- The most common adverse reactions with Briviact use in pediatric patients are similar to those seen in adults: somnolence/sedation, dizziness, fatigue, and nausea/vomiting.
- The recommended dosage of Briviact in pediatric patients aged 4 years to less than 16 years is based on body weight and is administered orally twice daily.
 - When initiating treatment, gradual dose escalation is not required.
 - Dosage should be adjusted based on clinical response and tolerability.
 - Consult the Briviact drug label for further dosing recommendations for pediatric patients, adult patients, and intravenous dosing.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.